 Home > Medical News > Medical Research Articles > WuXi Junuo Announces Its Cellular Immunotherapy Drug Has Successfully Benefited 200 Chinese Patients

WuXi Junuo Announces Its Cellular Immunotherapy Drug Has Successfully Benefited 200 Chinese Patients

 Last Update: 2022-05-16
 Source: Internet
 Author: User

Tags

class action database

stock exchange india

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

As the first product of WuXi Junuo, a class 1 new drug CAR-T product , ^Benoda® (Ruiji Orenza Injection), achieved the first patient reinfusion treatment in December 2017, and it will also be the first patient in 2022.

WuXi Junuo has successfully built a world-leading cellular immunotherapy technology and product development platform, as well as a product pipeline covering blood and solid tumors, and has carried out 9 clinical studies on blood and solid tumors

About Benoda® ( ^Rigiorenza Injection)

Benoda® (Ruiji ^Orenza Injection) is a CD19-targeting drug independently developed by WuXi Junuo on the basis of the CAR-T cell technology platform of Junuo Medical (a company of Bristol-Myers Squibb).

About WuXi Junuo

WuXi Junuo (HKEx: 2126) is an independent, innovative biotechnology company focused on the development, production and commercialization of cellular immunotherapy products

Forward-Looking Statements

The forward-looking statements contained in this release are based on management's existing expectations and beliefs and are subject to certain uncertainties or risks that could cause actual results to differ materially from those described

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Isocostic acid

CAS No.: 69978-82-1

Different Grade

$0.1/KG EXW

Flunixin meglumin

CAS No.: 42461-84-7

Different Grade

$0.1/KG EXW

BEST SELLER OF TRYPSIN INHIBITOR (91755-87-2) IN BULK QUANTITY

CAS No.: 91755-87-2

Industrial Grade

$300-350/MT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.